Comment on low FODMAP diet

Nutrition in Clinical Practice

Volumn 28, Issue 6, 2013, Pages 773-774

  Holmes, Rebecca ^a   Couzens, Katie ^a   Tsui, Vincci ^a   Hards, Lori ^a   Wiens, Kristin P ^b,c   Fenton, Tanis R ^a,d  

^a ALBERTA HEALTH SERVICES   (Canada)

^b MOUNT ROYAL UNIVERSITY   (Canada)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; FRUCTOSE; SORBITOL;

BACTERIAL GROWTH; BIFIDOBACTERIUM; CONSTIPATION; DIAGNOSTIC TEST; DIARRHEA; DIET THERAPY; FOOD INTAKE; FRUIT; HUMAN; INTESTINE FLORA; IRRITABLE COLON; LONG TERM CARE; LOW FODMAP DIET; MALABSORPTION; NOTE; OPTIMAL DRUG DOSE; PATIENT COUNSELING; PATIENT SELECTION; PERCEPTION; PLACEBO EFFECT; PRACTICE GUIDELINE; RISK FACTOR; SYMPTOM; TREATMENT RESPONSE; VEGETABLE;

DIET, CARBOHYDRATE-RESTRICTED; DIETARY FIBER; FOOD HABITS; HUMANS; IRRITABLE BOWEL SYNDROME;

EID: 84888612926     PISSN: 08845336     EISSN: 19412452     Source Type: Journal    
DOI: 10.1177/0884533613503554     Document Type: Note

References (14)

1. Barrett JS. Extending our knowledge of fermentable, short-chain carbohydrates for managing gastrointestinal symptoms. Nutr Clin Pract. 2013 ; 28: 300-306
2. Ong DK, Mitchell SB, Barrett JS, et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol. 2010 ; 25: 1366-1373
3. Kaptchuk TJ, Friedlander E, Kelley JM, et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One. 2010 ; 5: e15591
4. Staudacher HM, Lomer MC, Anderson JL, et al. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr. 2012 ; 142: 1510-1518
5. Kaptchuk TJ, Kelley JM, Conboy LA, et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ. 2008 ; 336: 999-1003
6. Conboy LA, Macklin E, Kelley J, Kokkotou E, Lembo A, Kaptchuk T. Which patients improve: characteristics increasing sensitivity to a supportive patient-practitioner relationship. Soc Sci Med. 2010 ; 70: 479-484
7. Shepherd SJ, Parker FC, Muir JG, Gibson PR. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol. 2008 ; 6: 765-771
8. Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther. 2009 ; 29: 508-501
9. Paineau D, Payen F, Panserieu S, et al. The effects of regular consumption of short-chain fructo-oligosaccharides on digestive comfort of subjects with minor functional bowel disorders. Br J Nutr. 2008 ; 99: 311-318
10. Olesen M, Gudmand-Høyer E. Efficacy, safety, and tolerability of fructooligosaccharides in the treatment of irritable bowel syndrome. Am J Clin Nutr. 2000 ; 72: 1570-1575
11. Barrett JS, Gibson PR. Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals?. Therap Adv Gastroenterol. 2012 ; 5: 261-268
12. Gibson PR, Shepherd SJ. Food choice as a key management strategy for functional gastrointestinal symptoms. Am J Gastroenterol. 2012 ; 107: 657-666
13. Rothman K, Greenland S, Lash T Modern Epidemiology. 3 rd ed.Philadelphia, PA: Lippincott, Williams, and Wilkins; 2012. Rothman K Greenland S Lash T, ed. Philadelphia, PA: Lippincott, Williams, and Wilkins ; 2012 :
14. Gasbarrini A, Corazza GR, Gasbarrini G, et al. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. Aliment Pharmacol Ther. 2009 ; 29: 1-49